Voluntis and AliveCor partners to help patients with cancer

Cardiotoxicity management for patients undergoing cancer treatment and facilitate for atrial fibrillation

Voluntis and AliveCor partner to advance management of Atrial Fibrillation for patients with cancer. photo AliveCor's

Voluntis, an Aptar Pharma company and leader in digital therapeutics, today announced that it has entered into a partnership agreement with AliveCor (AliveCor), a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology. Under the collaboration, AliveCor’s KardiaMobile device will be integrated with Theraxium, Voluntis’ regulated platform for digital therapeutics (DTx), to help address the challenges associated with cardiotoxicity management for patients undergoing cancer treatment and facilitate remote self-monitoring for atrial fibrillation (AFib).

Cardiotoxicity is a common complication associated with anti-cancer therapies such as
immunotherapy, radiotherapy and post-operation medication that causes damage to the
heart muscle and increases the risk of AFib. Clinical studies1 have observed that AFib
increases the risk of cardiovascular morbidity and mortality, it is associated with an almost
two-fold risk of mortality and a five-fold risk of stroke. During cancer therapy, the incidence rate of AFib affects the prognosis of tumor treatment and challenges the treatment plan.

“We are excited to be working with AliveCor so that we can together combine extensive
coaching and actionable directions for the management of atrial fibrillation,” said Pierre
Leurent, chief executive officer, Voluntis. “By bringing both our devices and capabilities
under the same umbrella, we hope to further improve the treatment adherence for people
living with cancer.”

The collaboration between Voluntis and AliveCor is aimed at improving patient experience,
treatment adherence and the prevention of treatment-related complications by facilitating
real-time monitoring and the detection of AFib with KardiaMobile, a small, hand-held
personal ECG (electrocardiogram) with sensors that enable a medical-grade, single-lead
ECG. KardiaMobile connects to the user’s smartphone using ultrasonic audio to record a
medical-grade ECG in just 30 seconds. If a heart rhythm abnormality is detected, patients can, in cooperation with their healthcare provider, use KardiaMobile to access information
about the heart health that can help them make decisions about their care and, if
necessary, adapt their treatment strategy.

“AliveCor is pleased to be working with Voluntis to improve cardiac monitoring protocols to
better serve people undergoing cancer treatment who may struggle to attend in-person
cardiological appointments due to immunosuppression, fatigue or other factors,” said Mark
Bogart, senior vice-president, US Healthcare, AliveCor. “This collaboration opens the door
to greater flexibility for patients and gives, healthcare providers access to more information to help guide clinical decision-making and patient care.”

By connecting its modular platform with digital biomarkers and sensor-based technologies,
Voluntis is creating a comprehensive device eco-system around its platform, allowing
patients to receive clinical recommendations based on objective measures and to seamlessly share their data with their care team.

Voluntis intends to make this new integration available to its life sciences partners as part of co-development projects based on the Theraxium platform.


Please enter your comment!
Please enter your name here